Skip to main content
    P

    Phio Pharmaceuticals Corp (PHIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.75
    -0.02 (-2.44%)

    Market Cap: $9.21M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Phio Pharmaceuticals Corp (PHIO) Financials: Revenue, Profit and Cash Flow

    Updated Aug 6, 2026. Financial statements from company filings, amounts in US dollars.

    Phio Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$8.70M, operating cash flow was -$7.98M and free cash flow was -$7.99M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$4.14M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.22M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$6.00KN/A100.0%-180400.0%-180433.3%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$21.00K-84.8%100.0%-42795.2%-42419.0%
    Dec 2018$138.00K+820.0%100.0%-5336.2%-5333.3%
    Dec 2017$15.00K-21.1%100.0%-93746.7%-83013.3%
    Dec 2016$19.00KN/A100.0%-47447.4%-47336.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$6.00K$0$0$0$21.00K$138.00K$15.00K$19.00K
    Gross profit$0$0$6.00K$0$0$0$21.00K$138.00K$15.00K$19.00K
    Research and development$4.62M$3.64M$6.33M$7.01M$8.89M$3.72M$4.30M$4.33M$10.07M$5.42M
    Operating income-$9.22M-$7.39M-$10.82M-$11.46M-$13.51M-$8.79M-$8.99M-$7.36M-$14.06M-$9.02M
    Net income-$8.70M-$7.15M-$10.83M-$11.48M-$13.29M-$8.79M-$8.91M-$7.36M-$12.45M-$8.99M
    EBITDA-$9.21M-$7.35M-$10.64M-$11.29M-$13.10M-$8.72M-$8.84M-$7.28M-$14.00M-$8.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$70.00K$0$0$0$6.00K$0
    Gross profit$0$0-$1.00K$0$0$0$35.00K$0$0$0$6.00K$0
    Operating income-$4.27M-$4.17M-$2.53M-$2.50M-$2.31M-$1.87M-$1.67M-$1.59M-$1.91M-$2.21M-$1.90M-$2.78M
    Net income-$4.14M-$4.00M-$2.37M-$2.39M-$2.17M-$1.77M-$1.63M-$1.52M-$1.85M-$2.15M-$1.90M-$2.78M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $21.03M were 97.9% of total assets of $21.49M, against total liabilities of $1.34M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$21.49M$5.74M$9.36M$12.81M$25.17M$15.74M$8.04M$15.32M$4.10M$13.40M
    Current assets$21.48M$5.74M$9.32M$12.45M$24.73M$15.16M$7.30M$15.15M$3.83M$13.11M
    Cash and equivalents$21.03M$5.38M$8.49M$11.78M$24.06M$14.24M$6.93M$14.88M$3.58M$12.91M
    Total liabilities$1.34M$1.01M$1.63M$1.97M$3.24M$2.72M$2.29M$1.74M$2.27M$2.54M
    Short-term debtN/AN/A$35.00K$135.00K$125.00K$116.00K$107.00KN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$231.00K$0N/AN/AN/A
    Shareholder equity$20.15M$4.72M$7.73M$10.84M$21.93M$13.02M$5.75M$13.58M$1.83M$10.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$14.31M$17.41M$21.49M$11.51M$11.30M$13.44M$5.74M$5.87M$5.30M$6.85M$9.36M$9.54M
    Total liabilities$1.71M$950.00K$1.34M$1.67M$1.21M$1.27M$1.01M$919.00K$1.52M$1.25M$1.63M$2.33M
    Cash and equivalents$13.00M$17.03M$21.03M$10.71M$10.78M$13.28M$5.38M$5.39M$4.70M$6.47M$8.49M$8.41M
    Shareholder equity$12.60M$16.46M$20.15M$9.84M$10.10M$12.17M$4.72M$4.95M$3.77M$5.60M$7.73M$7.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$7.98M-$7.11M-$10.75M-$12.13M-$11.86M-$8.80M-$8.64M-$7.52M-$9.51M-$7.76M
    Capital expenditures$12.00K$1.00K$5.00K$121.00K$51.00K$19.00K$72.00K$5.00K$203.00K$4.00K
    Free cash flow-$7.99M-$7.11M-$10.75M-$12.25M-$11.91M-$8.82M-$8.72M-$7.53M-$9.72M-$7.76M
    Dividends paidN/AN/AN/AN/AN/A$4.09M$1.00KN/AN/AN/A
    Investing cash flow-$12.00K$8.00K-$5.00K-$121.00K-$51.00K-$19.00K-$72.00K-$5.00K-$103.00K$5.35M
    Financing cash flow$23.64M$4.00M$7.41M-$26.00K$21.72M$16.13M$772.00K$18.82M$292.00K$10.20M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$4.04M-$4.00M-$2.08M-$2.08M-$2.54M-$1.27M-$1.37M-$1.95M-$1.78M-$2.01M-$2.37M-$2.90M
    Capital expendituresN/A$0$0$7.00K$3.00K$2.00K$1.00K$0$0$0$0$0
    Free cash flowN/A-$4.00M-$2.08M-$2.09M-$2.54M-$1.28M-$1.37M-$1.95M-$1.78M-$2.01M-$2.37M-$2.90M
    Last 12 quarters

    Frequently Asked Questions About PHIO

    What is Phio Pharmaceuticals' annual revenue?

    Phio Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Phio Pharmaceuticals profitable?

    No. Phio Pharmaceuticals reported net income of -$8.70M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PHIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.98M minus capital expenditures of $12.00K produced free cash flow of -$7.99M.

    How much debt does Phio Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $21.03M.